These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 23052398)

  • 1. Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer.
    Hastie E; Grdzelishvili VZ
    J Gen Virol; 2012 Dec; 93(Pt 12):2529-2545. PubMed ID: 23052398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update.
    Felt SA; Grdzelishvili VZ
    J Gen Virol; 2017 Dec; 98(12):2895-2911. PubMed ID: 29143726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell Cycle Arrest in G
    Bressy C; Droby GN; Maldonado BD; Steuerwald N; Grdzelishvili VZ
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30487274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Vesicular stomatitis virus in the fight against cancer].
    Janelle V; Poliquin L; Lamarre A
    Med Sci (Paris); 2013 Feb; 29(2):175-82. PubMed ID: 23452604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intertumoral heterogeneity impacts oncolytic vesicular stomatitis virus efficacy in mouse pancreatic cancer cells.
    Goad DW; Nesmelova AY; Yohe LR; Grdzelishvili VZ
    J Virol; 2023 Sep; 97(9):e0100523. PubMed ID: 37671865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virus specific tolerance enhanced efficacy of cancer immuno-virotherapy.
    Sobhanimonfared F; Bamdad T; Sadigh ZA; Choobin H
    Microb Pathog; 2020 Mar; 140():103957. PubMed ID: 31891795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fusogenic vesicular stomatitis virus combined with natural killer T cell immunotherapy controls metastatic breast cancer.
    Nelson A; McMullen N; Gebremeskel S; De Antueno R; Mackenzie D; Duncan R; Johnston B
    Breast Cancer Res; 2024 May; 26(1):78. PubMed ID: 38750591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vesicular Stomatitis Virus (VSV) G Glycoprotein Can Be Modified to Create a Her2/Neu-Targeted VSV That Eliminates Large Implanted Mammary Tumors.
    Gao Y; Bergman I
    J Virol; 2023 Jun; 97(6):e0037223. PubMed ID: 37199666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triptolide-mediated inhibition of interferon signaling enhances vesicular stomatitis virus-based oncolysis.
    Ben Yebdri F; Van Grevenynghe J; Tang VA; Goulet ML; Wu JH; Stojdl DF; Hiscott J; Lin R
    Mol Ther; 2013 Nov; 21(11):2043-53. PubMed ID: 23985699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy.
    Bishnoi S; Tiwari R; Gupta S; Byrareddy SN; Nayak D
    Viruses; 2018 Feb; 10(2):. PubMed ID: 29473868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retargeting Oncolytic Vesicular Stomatitis Virus to Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia.
    Betancourt D; Ramos JC; Barber GN
    J Virol; 2015 Dec; 89(23):11786-800. PubMed ID: 26378177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.
    Westcott MM; Liu J; Rajani K; D'Agostino R; Lyles DS; Porosnicu M
    J Virol; 2015 Aug; 89(15):7944-54. PubMed ID: 25995245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors.
    Wollmann G; Drokhlyansky E; Davis JN; Cepko C; van den Pol AN
    J Virol; 2015 Jul; 89(13):6711-24. PubMed ID: 25878115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer.
    Yu N; Puckett S; Antinozzi PA; Cramer SD; Lyles DS
    J Virol; 2015 May; 89(10):5250-63. PubMed ID: 25741004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus.
    Hastie E; Cataldi M; Moerdyk-Schauwecker MJ; Felt SA; Steuerwald N; Grdzelishvili VZ
    Oncotarget; 2016 Sep; 7(38):61601-61618. PubMed ID: 27533247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vesicular stomatitis virus: re-inventing the bullet.
    Lichty BD; Power AT; Stojdl DF; Bell JC
    Trends Mol Med; 2004 May; 10(5):210-6. PubMed ID: 15121047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic vesicular stomatitis virus administered by isolated limb perfusion suppresses osteosarcoma growth.
    Kubo T; Shimose S; Matsuo T; Fujimori J; Sakaguchi T; Yamaki M; Shinozaki K; Woo SL; Ochi M
    J Orthop Res; 2011 May; 29(5):795-800. PubMed ID: 21437961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma.
    Galivo F; Diaz RM; Wongthida P; Thompson J; Kottke T; Barber G; Melcher A; Vile R
    Gene Ther; 2010 Feb; 17(2):158-70. PubMed ID: 20016540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis.
    Gebremeskel S; Nelson A; Walker B; Oliphant T; Lobert L; Mahoney D; Johnston B
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Effects of M51R Vesicular Stomatitis Virus Treatment of Carcinomatosis From Colon Cancer.
    Day GL; Bryan ML; Northrup SA; Lyles DS; Westcott MM; Stewart JH
    J Surg Res; 2020 Jan; 245():127-135. PubMed ID: 31415934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.